Sangair team can share some exciting news.
Our ongoing pre-clinical study shows a clear effect. SangAspet™ lowers the number of viable bacteria (Pseudomonas Aeruginosa) in blood with average 52%, results achieved so far…
Simultaneously, the oxygen gas levels increase as well, which is believed to be beneficial to the patient.
The difference between the treated group of animals compared to the non-treated group of animals is not yet ready, but the trials are ongoing.
Other updates
Sangair have a strong patent family, approved in each country where applied. Most recently the patents were approved in Japan and Canada.
Boosted by the positive results from pre-clinical study, Sangar will now accelerate development of the SangAsept™ system by recruitment of critical competencies.
If interested in learning more of the technology and the future treatment, or if interested in investing in Sangair, please don’t hesitate to contact us.
Sincerely,
Henrik Rundgren, CEO